keyboard_arrow_up

Investigation Report on China Insulin Aspart Market, 2009-2018

Reportstack has announced a new market research publication on Investigation Report on China Insulin Aspart Market, 2009-2018. According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with more than 380 million patients worldwide.

On December 26, 2001 Novo Nordisk announced that the first insulin analogue insulin aspart (marketed by Novo Nordisk with the trade name "Novorapid") to treat insulin pump was approved by FDA. Insulin aspart was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analog, which was then harvested from a bioreactor. This analog has increased charge repulsion, which prevents the formation of hexamers, to create faster-acting insulin. Insulin aspart can reduce the level of postprandial glucose and glycated hemoglobin A (HbA1c). The onset of action is approximately 10 to 20 minutes. The global sales revenue of Novorapid in 2012 reached USD 2.78 billion, increased by 20% YOY. In April 2005, the first premixed insulin analogue Novomix 30 (composed of 30% soluble insulin aspart and 70% insulin aspart protamine) was launched in China.
Rapid economic growth in the last 30 years has changed Chinese people's eating habits and led to less physical activities. Incidence of diseases related to obesity keeps increasing. In China 40% of the youth aged 18-29 are potential diabetes patients with a higher risk of stroke, heart disease and renal failure. By the end of 2013 there were about 98 to 120 million diabetes patients in China. The market size of diabetes drugs is also increasing.
According to investigation on certain Chinese sample hospital market, the sales revenue of insulin aspart increased over 100 times from 2005 to 2013. Insulin aspart market in China is seized by Novo Nordisk. The investigation also states that some Chinese enterprises are applying for production of the generic drug, which is expected to appear on the market no sooner than 2015. The number of diabetes patients as well as the market size of insulin aspart in China is predicted to increase in the next few years.

Through this report, the readers can acquire the following information:
-Incidence of Diabetes in China
-Sales Price of Insulin Aspart in Hospital Market in China
-Process of Insulin Aspart Generic Drug in China
-Prospect of China Insulin Aspart Market

The following enterprises and people are recommended to purchase this report:
-Anti-diabetic Drug Manufacturers
-Medical Institutions
-Investors /Research Agencies Focusing on Anti-diabetic Drug

To view the table of contents and know more details please visit Investigation Report on China Insulin Aspart Market, 2009-2018.